Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. METHODS: In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). RESULTS: A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. CONCLUSIONS: Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“Between 65% and 96% of participants taking orforglipron achieved an A1C level below 7.0% at 26 weeks.174”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [174]
In the citing paper
“In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to −14.7% compared to −2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [25]
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“In a multicenter phase 2 trial, 272 participants (mean age, 54.2 years; mean BMI, 37.9 kg/m 2 ) were randomly assigned to 1 of 4 doses of oral orforglipron (12, 24, 36, or 45 mg) once daily or placebo, for 36 weeks (Wharton et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Self-citationLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Cited by
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Findings from the Global Burden of Disease Study 2021
Murray, C. J. L. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00769-4 · Cited by 1,057
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to − 14.7% compared to − 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25].”
InfluentialPalaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Following demonstration of robust efficacy in people with T2D and obesity in phase II studies 58,59 , orforglipron is currently being studied in separate phase III trials in T2D and obesity.”
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“29,56 In the SUSTAIN trials, semaglutide use has been shown to lower HbA1c, reduce BW and lower blood pressure when compared to placebo.”
BackgroundWestern diets and chronic diseases
Adolph, T. E., & Tilg, H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03165-6 · Cited by 191
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511774 · Cited by 189
Self-citationKloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 199
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“100,101 While oral formulations have demonstrated acceptable tolerability overall, gastrointestinal side effects remain common and may occur at similar or slightly higher rates than with injectable agents.”
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
“(19, 30).”
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“The most frequently reported adverse events were gastrointestinal, which led to the discontinuation of orforglipron in 10% to 17% of participants across different dosage groups [68].”
BackgroundGastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“A recent trial 214 involved 272 participants with a mean body weight of 108.7 kg and a BMI of 37.9.”
InfluentialNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Linz, D., Andrade, J. G., Arbelo, E., Boriani, G., BREITHARDT, G. E., Camm, A. J., Caso, V., Nielsen, J. C., Melis, M. D., Potter, T. J. R. D., et al. (2024) · EP Europace · doi:10.1093/europace/euae070 · Cited by 129
“133 134–138 Weight loss–inducing glucagon-like peptide (GLP)-1 receptor antagonists, e.g. 139–142 While regional patterns of care will vary, integrated risk factor and comorbidity management clinics and specialists can improve the prevention and treatment of concomitant conditions in patients with…”
BackgroundAnsari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
“199 Currently, investigations into GLP-1 RAs and similar drugs are underway to obtain approval for additional indications based on their diverse pharmacological effects.”
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“One in two people treated with the highest dose of 45 mg orforglipron lost ≥15% body weight 139 .”
InfluentialEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
“There is also a novel non-peptide GLP1RA, orforglipron, that causes significant weight loss in overweight and obese patients, but it is not yet FDA-Cells approved [30].”
BackgroundIsmaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Mesinovic, J., Fyfe, J. J., Talevski, J., Wheeler, M. J., Leung, G. K. W., George, E. S., Hunegnaw, M. T., Glavas, C., Jansons, P., Daly, R. M., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0112 · Cited by 114
“Dual-agonists appear to confer additional benefits over mono-agonists, and other dual-and tri-agonists currently in clinical trials show great promise (NCT04478708 [194,195]).”
BackgroundMoiz, A., Levett, J. Y., Filion, K. B., Peri, K., Reynier, P., & Eisenberg, M. J. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.04.041 · Cited by 88
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 109
“237 In this rapidly evolving field, therapies under investigation also include the so-called ‘triple G’ receptor agonists (GLP-1, GIP, and glucagon) 238 and amylin agonists alone or combined with other gut hormone analogues, 239 with the potential for even greater reductions in weight.”
Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00507-0 · Cited by 81
Self-citationMoll, H., Frey, E., Gerber, P., Geidl, B., Kaufmann, M., Braun, J., Beuschlein, F., Puhan, M. A., & Yebyo, H. G. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102661 · Cited by 73
Karakasis, P., Patoulias, D., Pamporis, K., Stachteas, P., Bougioukas, K. I., Klisic, A., Fragakis, N., & Rizzo, M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155710 · Cited by 66
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1364503 · Cited by 78
“Phase II clinical trials are ongoing, and promising weight reduction effects are noted (74).”
BackgroundLe, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Early trials have found benefits for both obesity [172] and diabetes [173], expanding oral GLP-1 RA choices.”
BackgroundEffectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
“It is evident that numerous pharmaceutical manufacturers are prepared to introduce novel oral medications into the market [24].”
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
A narrative review of approved and emerging anti-obesity medications
Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A. H. I., Hussain, F., Yousif Khidir, I., & Abdelnassir, Z. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101757 · Cited by 51
“The drug improved both the weight and metabolic features of obesity (Wharton S et al. 2023).”
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review
Paschou, I. A., Sali, E., Paschou, S. Α., Ψαλτοπούλου, Θ., Nicolaidou, E., & Stratigos, A. J. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20694 · Cited by 56
“14,16,17 21–24 Further research is required to show the exact mechanisms by which GLP-1RA affects skin physiology and disease.”
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp5765 · Cited by 52
Wang, Z., Yang, S., Liu, L., Mao, A., Kan, H., Yu, F., Ma, X., Feng, L., & Zhou, T. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70053 · Cited by 56
Self-citationGLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51
“Additionally, the phase 2 trial of orforglipron, a novel non-peptide oral GLP-1 receptor agonist, included adults up to 75 years, and demonstrated mean weight loss of 14.7% (vs. 2.3% placebo) over 36 weeks [121]; with a phase 3 currently underway.”
InfluentialIncretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“In obese, non-diabetic individuals, orforglipron administration for 36 weeks in a phase 2 trial, ranging from 12 mg to 45 mg doses, resulted in dose-dependent weight loss of up to 14.7%, accompanied by improvements in cardiometabolic risk factors [109] (Figure 6).”
BackgroundInfluentialStructural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Huang, Y., Liao, W., Huang, J., Lin, Y., Yang, S., Huang, C., Wang, C., & Su, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15869 · Cited by 44
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“However, despite the un-paralleled success achieved with the treatment of obesity using GLP-1 analogues alone or in combination with GIP agonists (219-223), comparisons based on animal studies and theoretical considerations can be considered and are warranted.”
InfluentialRosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W.-S., Liu, R., Zhao, Y., Manghi, F. P., Abalos, F., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00202-3 · Cited by 50
Self-citationMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In a phase 2 study as a once daily therapy for 36 weeks in 272 people with obesity (mean BMI 37.9 (108.7 kg)) [61].”
InfluentialGLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“Maintenance therapy using orally active formulations of GLP-1RAs such as Rybelsus (oral sema-glutide) (129); or the small molecule GLP-1R partial agonist orforglipron (130) may also represent a viable strategy.”
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis
Guo, X., Asthana, P., Zhai, L., Cheng, K. W., Gurung, S., Huang, J., Wu, J., Zhang, Y., Mahato, A. K., Saarma, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45452-3 · Cited by 47
“…listed in association with current therapies are not critical issues for tirzepatide, semaglutide, and orforglipron, clinical trials have revealed that a quarter of participants taking one of these drugs reported that they discontinued the treatments due to gastrointestinal adverse events 8,9 .”
BackgroundCamilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
Garvey, W. T., Mahle, C. D., Bell, T., & Kushner, R. F. (2024) · Obesity Science & Practice · doi:10.1002/osp4.756 · Cited by 44
“Furthermore, the advent of small ‐ molecule oral GLP ‐ 1 receptor agonists 35 will also hopefully result in reduced costs and improve access to AOMs.”
BackgroundWang, L., Wang, Q., Xiong, Y., Shi, W. F., & Xiao, Q. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s540103 · Cited by 46
“120 Various dietary strategies have been proposed to promote weight loss, though the optimal macro-nutrient composition for obesity treatment remains to be determined.”
Chu, J., Zhang, H., Wu, Y. F., Huang, Y., Zhu, T., Zhou, Z., & Wang, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103464 · Cited by 45
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“…agonists such as semaglutide or liraglutide, orforglipron does not require injection, cold-chain storage, or co-formulation with absorption enhancers such as sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC), making it a potentially more accessible and convenient option for patients [75].”
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01554-1 · Cited by 38
“…results, two phase 2 randomized clinical trials were designed without food or water restrictions, wherein orforglipron treatment demonstrated robust glycemic control and body weight reduction in a 26-week study in participants with T2D and in a 36-week study in participants with obesity [26, 27].”
BackgroundSelf-citationDutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
Amin, N. B., Frederich, R. C., Tsamandouras, N., Haggag, A. Z., Schuster, T., Żmuda, W., Palmer, A., Vasas, S., Buckley, G., Smith, T. R., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16005 · Cited by 37
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“39,40 The potential for improved patient adherence with FIGURE 1 Potential mechanisms of GLP-1, GIP and GCG for weight loss in overweight or obese adults without type 2 diabetes.”
Kokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 34
A revolution in obesity treatment
Lingvay, I., & Agarwal, S. (2023) · Nature Medicine · doi:10.1038/s41591-023-02538-7 · Cited by 37
Cryo-electron microscopy-based drug design
Cebi, E., Lee, J., Subramani, V. K., Bak, N., Oh, C., & Kim, K. K. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1342179 · Cited by 38
“In a recent report after phase 2 clinical studies (ClinicalTrials.gov ID: NCT05048719 and NCT05051579), orforglipron showed pharmacodynamic and safety pro fi les similar to those of already approved injectable drugs and promising results for phase 3 studies (Frias et al., 2023; Wharton et al., 2023).”
BackgroundBailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“However, daily oral administration of the small molecule, orforglipron showed promise in phase 2 clinical trials producing significant weight reduction and improvement in lipid profile while mild to moderate adverse events were similar to those with injectable GLP-1 receptor agonists [129,130].”
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Li, H., Yu, G., Huang, Q., Yang, B., Nie, J., Liu, Y., & Tu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116150 · Cited by 38
Yin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 35
Buckeridge, C., Cobain, S., Bays, H. E., Matsuoka, O., Fukushima, Y., Halstead, P., Tsamandouras, N., Sherry, N., Gorman, D. N., & Saxena, A. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16534 · Cited by 38
The Extraordinary Benefit of Nature’s Chemistry to Health, Society, and the Economy
Moore, B. S., & Newman, D. J. (2025) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5c00554 · Cited by 32
Colwill, M., Povlsen, S., Pollok, R., Patel, K., Goodhand, J., Ahmad, T., & Honap, S. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf167 · Cited by 40
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
“Promising results of phase II trials of novel agents including orforglipron (small-molecule oral GLP-1RA) 31 , retatrutide (GIP–glucagon–GLP-1 receptor triple agonist) 32 , and combination amylin analogue–GLP-1RA therapy with cagrilintide and semaglutide 33 illustrate the ongoing progress in…”
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Lee, W., Kipp, Z. A., Pauss, S. N., Martinez, G. J., Bates, E. A., Badmus, O. O., Stec, D. E., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20242825 · Cited by 32
“GLP1RA and DPP4i results are impactful; in some instances, people with obesity lost more than 10% of body weight [192,193].”
Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Cross-Talk of NADPH Oxidases and Inflammation in Obesity
Morawietz, H., Brendel, H., Diaba‐Nuhoho, P., Catar, R. A., Perakakis, N., Wolfrum, C., & Bornstein, S. R. (2023) · Antioxidants · doi:10.3390/antiox12081589 · Cited by 30
Evolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 30
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
“Compared to peptide GLP-1 receptor agonists, orforglipron, exhibits less receptor desensitization by increasing cyclic AMP signaling [105].”
InfluentialSemaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“In addition, oral non-peptide GLP-1 RAs, such as orforgli-pron [176] and danuglipron [177], are being tested in early phase clinical studies.”
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Bellavance, D. R., Chua, S. G., & Mashimo, H. L. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00995-3 · Cited by 33
“In overweight and obese individuals, GLP-1 RAs are highly efficacious in promoting loss of > 10% total body weight [4, 5].”
Sinha, B., & Ghosal, S. (2025) · Obesity · doi:10.1002/oby.24360 · Cited by 31
“Nineteen RCTs ( N = 29,506) evaluated liraglutide [4, 8–11], oral and injectable semaglutide [3, 12, 13, 17–21], orforglipron [12], tirzepatide [22–24], retatrutide [15, 16], survodutide [14], and placebo over 36–104 weeks (Table 1).”
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
“Further details of the clinical trial protocols, study populations, statistical analysis plans, and study outcomes have been published [25, 26].”
InfluentialSelf-citationGut microbiota in inflammation and colorectal cancer: A potential Toolbox for Clinicians
Grellier, N., Severino, A., Archilei, S., Kim, J., Gasbarrini, A., Cammarota, G., Porcari, S., & Benech, N. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101942 · Cited by 31
Effect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
“Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists (Wharton, et al., 2023).”
BackgroundHistory of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Metadata
- Authors
- Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & Konig, M.
- Affiliations
- Eli Lilly (United States) (US)
- From McMaster University, York University, and Wharton Weight Management Clinic — all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.B.), and Velocity Clinical Research at Medical City, Dallas (J.R.) — both in Texas; Alliance for Multispecialty Research, Norman, OK (L.C.); and Eli Lilly, Indianapolis (S.R., R.L., X.M., K.J.M., A.H., D.R., E.P., C.K., M.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-07
- Volume
- 389
- Issue
- 10
- Pages
- 877-888
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4381716537
- Semantic Scholar
- db8284957df7f480bc8b5957f73388bfd42590cf
- Cited by
- 478
- References
- 19
- Citations by year
- 2026: 125 · 2025: 175 · 2024: 133 · 2023: 45
- FWCI
- 74.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity, weight loss, cardiometabolic risk, gastrointestinal adverse effects, dose escalation, overweight adults, weight change, drug safety and efficacy, weight-related comorbidities, dose-response relationship, dose-limiting adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.